Open Access

Prospects for clinical benefit with CETP inhibition in light of current and future trials.

Topic: Metabolism and metabolic syndromes
Sponsored by Cleveland Clinic

Congress Presentation

About the speaker

Professor A Michael Lincoff

Cleveland Clinic Hospital, Cleveland (United States of America)
6 presentations
0 follower

3 more presentations in this session

Unmet medical needs with current agents and residual CV risk: rationale for developing new agents.

Speaker: Professor S. Nissen (Cleveland, US)


New horizons for the statin intolerant patients: current and future therapeutic options.

Speaker: Doctor L. Cho (Cleveland, US)


The science of HDL and reverse cholesterol transport – Are we still hopeful?

Speaker: Professor J. Kastelein (Amsterdam, NL)


Access the full session

Cardiovascular risk reduction and lipid management: state of the science

Speakers: Professor A. Lincoff, Professor S. Nissen, Doctor L. Cho, Professor J. Kastelein

About the event


ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb